Compare BZFD & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZFD | QTTB |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6M | 40.9M |
| IPO Year | N/A | N/A |
| Metric | BZFD | QTTB |
|---|---|---|
| Price | $0.95 | $3.38 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | ★ 494.7K | 257.1K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $184,927,000.00 | N/A |
| Revenue This Year | $0.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $339.34 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $1.35 |
| 52 Week High | $3.12 | $6.37 |
| Indicator | BZFD | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 45.19 | 60.92 |
| Support Level | $0.90 | $3.08 |
| Resistance Level | $1.02 | $3.50 |
| Average True Range (ATR) | 0.08 | 0.21 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 30.00 | 82.22 |
BuzzFeed Inc is a tech-powered, diversified media company that reaches hundreds of millions globally through its cross-platform news and entertainment network. The company produces articles, lists, quizzes, videos, and original series; lifestyle content through brands including Tasty, social food network; original reporting and investigative journalism through BuzzFeed News and HuffPost; an industry- affiliate business, strategic partnerships, licensing and product development through BuzzFeed Commerce; and original productions across broadcast, cable, SVOD, film and digital platforms for BuzzFeed Studios.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function.